Port Delivery System Sustains nAMD Control Over 5 Years

Five-year data from the Portal extension study show durable outcomes with reduced treatment burden for Genentech’s Susvimo.

By: Jim Gallagher, senior managing editor

Retinal Physician August 9, 2025 Vol 22, Issue July/August 2025

Clinical Report: Port Delivery System Sustains nAMD Control Over 5 Years

Overview

{'mean_BCVA_decline': 'Specify if the 7-letter decline is statistically significant.'}

Background

Neovascular age-related macular degeneration (nAMD) is a leading cause of vision loss in older adults, necessitating effective long-term treatment strategies. The Port Delivery System (PDS) offers a novel approach to sustained anti-VEGF delivery, potentially reducing the frequency of treatments compared to traditional intravitreal injections. Understanding the long-term efficacy and safety of the PDS is crucial for optimizing patient outcomes.

Data Highlights

{'table_format': 'Ensure proper clinical reporting format.'}

Key Findings

{'statistical_significance': 'Add p-values or confidence intervals where applicable.'}

Clinical Implications

{'patient_population': 'Detail which specific patient demographics may benefit from PDS.'}

Conclusion

{'future_studies': 'Emphasize the need for ongoing research and monitoring.'}

PentaVision

Retinal Physician